In a preclinical model of neuroblastoma, Dearling et al. recently demonstrated the potential interest for a theranostic approach of [<sup>64</sup>/<sup>67</sup>Cu]Cu-SARTATE for the detection and treatment of SSTR2-positive neuroblastoma lesions in pediatric patients whose widespread metastases survive initial therapy as minimal residual disease (MRD). The gene discussed is SSTR2; the disease is neuroblastoma.